Impact of Sacubitril/Valsartan in Cardiac Reverse Remodeling in Ischemic vs. Nonischemic Cardiomyopathy
Guideline directed medical therapy with beta blockers, ACEi/ARBs, and aldosterone antagonists with the goal of affecting cardiac reverse remodeling (CRR) has previously been the cornerstone of management of patients with heart failure with reduced ejection fraction (HFrEF). More recently, PARADIGM-HF demonstrated the superiority of sacubitril-valsartan to enalapril in reducing HF hospitalizations as well as cardiac and all-cause mortality. Other studies demonstrated that ARNI therapy may enhance CRR to a greater degree than ACEI or ARB therapy alone.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: O. Safdar, A. Ervin, S. Cozzi, I. Danelich, M. Shah, A. Vishnevsky, R. Alvarez, P. Pirlamarla Tags: (580) Source Type: research
More News: Beta-Blockers | Cardiology | Cardiomyopathy | Diovan | Enalapril | Heart | Heart Failure | Heart Transplant | Lung Transplant | Study | Transplant Surgery | Transplants